Concomitant overexpression of Activin A and p63 is associated with poor outcome in oral cancer patients.
Dhanashree MundheRohit WagholeSagar PawarRupa MishraArusha ShettyPoonam GeraSadhana KannanTanuja TeniPublished in: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2020)
Activin A overexpression is an early event in oral cancer pathogenesis and can independently predict survival. Moreover, in combination with p63 overexpression, it served as a better marker for poor prognosis. Activin A could thus be a promising target for improved outcome in oral cancer patients.